












httpOutcomes of fenestrated endovascular repair of
juxtarenal aortic aneurysm
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Objective: To evaluate late outcomes after fenestrated endovascular aortic repair (f-EVAR) in a tertiary European referral
center.
Methods: In 2009, we published short- and midterm results after f-EVAR in the ﬁrst 54 patients treated with this
technique at our center between September 2002 and June 2007. In this paper, we provide long-term follow-up of the
same patient cohort with the main focus on target vessel (TV) patency, renal function, reinterventions, and survival.
Results: A total of 54 patients were included in this study. Median age was 72 years (interquartile range [IQR],
68-76 years) at primary operation, and 85% were men. Median preoperative aneurysm diameter was 60 mm (IQR,
53-66 mm). One hundred thirty-four vessels were targeted (mean, 2.5 per patient), and 96 TV stents were placed. The
median clinical follow-up was 67 months (IQR, 37-90 months), and computed tomography follow-up was 60 months
(IQR, 35-72 months). Aneurysm diameter decreased $5 mm in 39% 6 7% at 12 months, 64% 6 8% at 36 months, and
71% 6 8% at 60 months. Primary TV patency was 94% 6 2% at 12 months, 91% 6 3% at 36 months, and 90% 6 3% at
60 months. Glomerular ﬁltration rate decreased by 17% at 59 months (IQR, 26-73 months) follow-up (60 [IQR, 46-79]
vs 50 [IQR, 38-72] mL/min/1.73 m2; P < .001), and one patient became dialysis-dependent secondary to a renal stent
occlusion. Reintervention-free survival was 88% 6 5% at 12 months, 69% 6 7% at 36 months, and 56% 6 5% at
60 months. At least one reintervention was done in 37% of patients, of which 29% were endoleak-related, 26% TV-related,
13% graft-limb-related, and 32% due to other causes. The majority of reinterventions (68%) were based on complications
detected on routine follow-up. Estimated overall survival was 93% 6 4% at 12 months, 76% 6 6% at 36 months, and
60% 6 7% at 60 months. In total, 54% of the patients died during the 10-year study period, where 9% died of aneurysm-
related causes.
Conclusions: Long-term mortality after f-EVAR is high, but most patients die from nonaneurysmal causes. Aneurysm-
related mortality is associated with technical complications that can be reduced with increased experience. Reinterven-
tions are common, and most complications are detected on routine follow-up. (J Vasc Surg 2014;59:115-20.)The Zenith fenestrated abdominal aortic aneurysm
endovascular graft was approved by the U.S. Food and
Drug Administration (FDA) in April 2012, and conse-
quently, an explosive increase in fenestrated endovascular
aortic repair (f-EVAR) is to be expected in the United
States. At our center, the ﬁrst f-EVAR was performed in
late 2002, and the number of patients treated with this
method has gradually increased, with close to 50 proce-
dures performed annually during the past few years. In
2009, we published short- and midterm results of our
initial experience with the fenestrated device, which
included a learning curve for the procedure.1 Since
then, numerous authors have published promising
short-term results, but long-term follow-up is lacking.
In this paper, we provide long-term follow-up of ourthe Vascular Center, Skåne University Hospital.
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://dx.doi.org/10.1016/j.jvs.2013.07.009initial experience for better understanding of late compli-
cations and mortality in this patient group.METHODS
All patients treated with f-EVAR between September
2002 and June 2007 were prospectively enrolled in a data-
base incorporating multiple variables such as stent graft
design and patient demographics. Work-up consisted of
clinical exam and high-resolution spiral computed tomog-
raphy (CT) scans, which were reconstructed in a vascu-
lar three-dimensional workstation (www.terarecon.com).
During this period, all patients who were anatomically
unﬁt for standard infrarenal EVAR and deemed at high
risk for open aneurysm repair were considered for
f-EVAR. The Zenith device (William Cook Europe, Bjae-
verskov, Denmark) formed the foundation of the fenes-
trated graft in all cases. Follow-up consisted of clinical
exam at 1 month as well as CT scans and plain abdominal
ﬁlms after 1 month, 1 year, and yearly thereafter. As part
of the follow-up protocol, medical records and follow-up
images were electronically linked to our center for evalu-
ation by the operating surgeon and the corresponding
author. Deaths were veriﬁed through a national register,
and medical records were obtained for further analysis
when aneurysm-related death was suspected. End points
were target vessel (TV) stenosis or occlusion, secondary115
Fig 1. A scatter plot demonstrating changes in aneurysm diameter
for each patient from the preoperative computed tomography
(CT) scan to the end of CT follow-up (median, 60 months). The
indication for treatment was abdominal aortic aneurysm (AAA) in
44 patients, residual AAA after open aneurysm surgery in three
patients, juxtarenal pseudoaneurysm secondary to aortic ulceration
in three patients, residual AAA after conventional infrarenal EVAR
in two patients, and aortic dissection with a secondary aneurysm in
two patients.
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deﬁned as all deaths occurring within 30 days from the
initial procedure as well as late deaths associated with
stent graft complications. Endoleaks, changes in aneu-
rysm size, and changes in glomerular ﬁltration rate
(GFR) over time were also registered. Aneurysm diameter
changes were considered signiﬁcant when $5 mm. A
detailed study method has been published earlier and
covers our initial experience with fenestrated devices.1
Statistics. Continuous data are presented as median
with interquartile range in parenthesis. The Wilcoxon
signed-rank test was used for analyzing changes in aortic
diameter and GFR. Estimations of mortality, TV patency,
changes in aortic diameter, and reintervention-free
survival were done with Kaplan-Meier and life-table anal-
ysis (presented as percentages 6 standard error). SPSS
version 20.0 (SPSS Inc, Chicago, Ill; www.spss.com) was
used for all statistical analysis, and P < .05 was considered
statistically signiﬁcant.
RESULTS
A total of 54 patients were included in the study.Median
age was 72 (range, 68-76) years, and 85% were men. All
patients were asymptomatic and were anatomically unsuit-
able for infrarenal EVAR. The median clinical follow-up
was 67 (range, 37-90)months, CT follow-upwas 60 (range,
35-72) months, and GFR follow-up was 59 (range, 26-73)
months. Patient demographics, operative results, and
short-term outcomes have been published earlier.1
Aneurysm diameter. Median aortic diameter was 60
(range, 53-66) mm on the preoperative CT scan, 54
(range, 46-64) mm after 1 year, 51 (range, 39-61) mm
after 3 years, and 50 (range, 39-50) mm after 5 years
(P < .001). Aneurysm diameter decreased $5 mm in
39% 6 7% of patients at 12 months, 64% 6 8% at
36 months, and 71%6 8% at 60 months. Changes in aneu-
rysm diameter over time are presented in Fig 1.
Endoleaks. Large balloon-expandable stents were
used intraoperatively to treat type I (n ¼ 11) or type III
(n ¼ 3) endoleaks in 13 patients. Completion angiography
showed type I endoleaks in three patients, two proximal
and one distal. The proximal leaks had resolved on pre-
discharge CT scans, and the distal leak was treated with
a giant Palmaz stent on postoperative day 4. Late type I
endoleaks were observed in ﬁve patients. All leaks were
associated with the distal sealing zones and successfully
treated with distal extensions after their appearance on
1-month, 1-year, 2-year, 3-year, and 5-year CT scans.
Three of the patients required treatment bilaterally.
Type II endoleaks were observed in 13 patients on
completion angiography and persisted in three patients at
1 year. One patient was treated with coil embolization of
the inferior mesenteric artery after 44 days (endoleak on
1-month CT scan) and another with glue embolization
of lumbar arteries after 553 days (expanding aneurysm
sac). Both endoleaks reappeared on 3-year CT scans. In
the ﬁrst case, the leak was successfully treated with glue
embolization, but in the second case, the patient died ofnonaneurysm-related causes prior to any reintervention.
No other type II endoleaks were treated.
One patient had a type III endoleak on the completion
angiography but died from complications due to bowel
ischemia prior to any control angiography. One patient
with an expanding aneurysm sac without signs of endoleak
during follow-up died from aneurysm rupture secondary to
a separation of the proximal and bifurcated components
3 years postoperatively after emergency conversion to
open repair.
TV patency. One hundred thirty-four vessels were
targeted (mean, 2.5 per patient), and 96 TV stents were
placed (all balloon-expandable, 72% uncovered, 28%
covered). Estimated primary TV patency was 94% 6 2% at
12 months, 91% 6 3% at 36 months, and 90% 6 3% at
60 months, with primary-assisted patency of 96% 6 2% at
12 months and 93% 6 2% at 36 and 60 months. Seven
renal angiographies were performed, leading to three
reinterventions at 1 year, one reintervention at 2 years, and
one reintervention at 4 years. Two unstented renal arteries
early in the series became partially covered by the stent
graft fabric without causing a hemodynamically signiﬁcant
stenosis or occlusion during the follow-up period. Two
other stented renal arteries had a signiﬁcant stenosis on
1-year CT follow-up and were not treated. In one case, the
patient had disseminated malignant disease, and in the
other case, the kidney had shrunken and was non-
functional at the time of diagnosis. Additionally, one
superior mesenteric artery (SMA) was stented due to an
asymptomatic stenosis detected at 6-year follow-up (3.6%
of unstented SMA scallops).
Fig 2. Kaplan-Meier estimate of primary and primary-assisted
target vessel (TV) patency over time.
Fig 3. A scatter plot demonstrating changes in glomular ﬁltration
rate (GFR) for each patient from the initial preoperative
measurement to the end of follow-up (median, 59 months).
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 1 Kristmundsson et al 117Eight (6%) of the TVs occluded: three SMAs and ﬁve
renal arteries. Two SMAs occluded prior to the
12-month CT scan and one 6 months postoperatively
(10.7% of unstented SMA scallops). In all cases, the
patients were asymptomatic, and no further intervention
was necessary. One renal artery was sacriﬁced to seal
a type I endoleak intraoperatively, one occluded prior to
a 12-month CT scan, and three occluded after 3 years
(all stented primarily through 6-  8-mm renal fenestra-
tions). Of those late occlusions, one patient became
dialysis-dependent due to a reduced arterial circulation in
the other kidney without any signs of stenosis on angiog-
raphy. TV patency over time is presented in Fig 2.
Renal function. One patient was on dialysis prior to
endografting. The median preoperative GFR was 60
(range, 46-79) mL/min/1.73 m2, and 50% of the patients
had a baseline renal dysfunction at the time of the initial
procedure (GFR #60). Nineteen patients (35%) developed
at least a transient decrease in GFR (>30%) in the imme-
diate postoperative period. At last follow-up, GFR
decreased to 50 (38-72; P < .001) in the whole patient
cohort, and seven (26%) of the patients with normal
preoperative renal function had developed a decrease in
GFR >30%. Of those, one patient had developed a renal
stenosis with assisted primary patency after 24 months. The
remaining six patients had no signs of decreased renal
perfusion on CT angiography during follow-up. Of the
patients with preoperative renal dysfunction, one patient
became dialysis-dependent due to a renal artery occlusion
3 years postoperatively, and six patients (22%) deteriorated
successively with >30% decrease in GFR without any signs
of decreased perfusion on CT angiography during follow-
up. Changes in renal function over time are presented in
Fig 3.
Reinterventions. Reintervention-free survival rate was
88% 6 5% at 1 year, 69% 6 7% at 3 years, and 56% 6 5% at
5 years (Fig 4). Thirty-one reinterventions were done in 20
(37%) patients. Of those, 29% were endoleak-related, 26%
TV-related, 13% graft-limb-related, and 32% due to other
causes. The majority of reinterventions (68%) were based
on complications detected on routine follow-up. Reinter-
ventions are presented in Table I.
Survival. Estimated overall survival was 93% 6 4% at
1 year, 76% 6 6% at 3 years, and 60% 6 7% at 5 years.
Twenty-nine patients died during the follow-up period
(54%), and two of those within 30 days of the initial
procedure (3.7%). One patient developed bowel ischemia
secondary to mesenteric artery embolization and died after
13 days from multiorgan failure. One patient died after
15 days from complications secondary to retroperitoneal
bleeding, which was caused by a renal artery perforation
during the procedure. Three late deaths were aneurysm-
related. One patient died from massive bleeding at an
outside hospital 6 months after the primary procedure
during surgery of the groin related to infection. One
patient died of aneurysm rupture due to separation of the
proximal and bifurcated components after 35 months, and
one patient died of bowel ischemia secondary to graftinfection after 72 months. In total, 9% of all deaths were
aneurysm-related. Patient demographics and graft conﬁg-
uration of the cohort remaining in the study at 1, 3, and
5 years is presented in Table II, and survival function for
all-cause mortality is given in Fig 5.
DISCUSSION
The Zenith fenestrated abdominal aortic aneurysm
endovascular graft has been on the market in the European
Union since late 2005 and was FDA approved in the U.S.
in April 2012. As with most endovascular treatments,
Fig 4. Kaplan-Meier estimate of the reintervention-free survival.
Majority (68%) of reinterventions were based on ﬁndings detected
on routine computed tomography (CT) follow-up.
Table I. Reinterventions during follow-up
Cause Number Reintervention
Type I endoleak 5 Distal limb extensions (5; 3
bilaterally)
Type II endoleak 4 Glue emboliztion (2), coiling
IMA (1), untreated (1).
TV stenosis 8 Renal PTA (5), SMA PTA (1),
untreated (2)
Graft limb stenosis 1 Stenting (1)
Graft limb occlusion 3 Thrombectomy and patch in
CFA (1), femoro-femoral
crossover (2)
Other 10 Pressure measurements in
nonshrinking aneurysm (5),
endostapling due to
migration (1), coiling of renal
artery bleeding (1), drainage
of hematoma (1), drainage of
infection (1), thrombolysis of
graft occlusion (1).
CFA, Common femoral artery; IMA, inferior mesenteric artery; PTA,
percutaneous transluminal angioplasty; SMA, superior mesenteric artery;
TV, target vessel.
The majority of reinterventions (68%) were based on ﬁndings on routine
CT follow-up.
Table II. Comorbidities and number of fenestrations in
patients remaining in the study at 12, 36, and 60 months
of follow-up
12 months 36 months 60 months
Diabetes 12% 12% 12%
Coronary heart disease 43% 45% 49%
Heart failure 14% 14% 9%




Renal failure 50% 49% 40%
Mean number of fenestrations 2.5 2.5 2.5
Fig 5. Kaplan-Meier estimate of the survival function for all-cause
mortality. Overall mortality in the study period was 54%, with
abdominal aortic aneurysm-related mortality of 9%.
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and data until now have conﬁrmed that this method works
in the short- to midterm. Due to the novelty of this tech-
nique, reports on long-term follow-up in this patient group
are lacking.
Operative mortality has been reported between 0.2%
and 2.6%,2-8 with a pooled proportion mortality rate of2.0% in meta-analysis.9 This compares favorably with that
of open surgical repair of short neck aneurysm, which has
operative morality rates of 2.5% to 5.8%.10,11 In our series,
operative mortality occurred in two patients (3.7%), and
both deaths were secondary to technical complications
during the procedure, indicating that catheterization and
stenting of TVs add a level of complexity. With increased
experience, technical failures are likely to decrease, as no
operative deaths occurred from technical failures at our
center in the 100 consecutive patients treated (unpublished
data). A major concern is the late aneurysm deaths and
overall mortality in our series. In one case, death occurred
secondary to device failure missed on routine follow-up.
Separation of the proximal and bifurcated components
resulted in repressurization of the aneurysm sac with
JOURNAL OF VASCULAR SURGERY
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procedure despite an emergency open repair. The possi-
bility of distal movement of the bifurcated component after
f-EVAR is indeed deliberate to avoid displacement of the
proximal fenestrated graft, which might result in crushing
of the TV bridging stents. When the component overlap
is insufﬁcient, especially in a large aneurysm sac, total dislo-
cation of the components can occur. Even if clinical conse-
quences are rare, reported intercomponent migration is
found in up to 13% of patients during follow-up,12 making
detailed evaluation of component overlap necessary on
follow-up CT scans. In this particular patient, component
separation (<2 stent overlap) was only noted retrospec-
tively. We now routinely evaluate intercomponent migra-
tion between the fenestrated and bifurcated components
by measuring the distance between gold markers on plain
abdominal ﬁlms and/or CT reconstructions during
follow-up. Other late aneurysm-related deaths were
secondary to infection. In one case, the patient died at an
outside hospital due to bleeding associated with abscess
drainage in the groin, and in the other case, the visceral
segment of the graft occluded in a patient with a chronic
stent graft infection.
Additionally, 24 (44%) of the patients died of other
causes, making overall mortality 54% at a median follow-
up of 67 months. Although survival was better than in an
untreated cohort of patients unﬁt for open surgery,13 the
mortality rate is in line with overall mortality in patients
with peripheral vascular disease,14 indicating severe comor-
bidities in this patient group. This might partially reﬂect the
fact, that during this time period, only patients deemed
unﬁt for open surgery were considered for fenestrated
repair. Considering the high operative mortality after
open surgery,15 we now offer f-EVAR as the ﬁrst-line treat-
ment in all patients with juxtarenal aneurysm, which might
increase survival in the long term.
As reported in our previous publication, most TVs are
successfully catheterized during the procedure. At 1 year,
estimated primary patency of all TVs was 94% 6 2% and
primary-assisted patency 96% 6 2%, which compares well
to earlier reports of fenestrated and branched devices.16,17
Of eight TV occlusions, ﬁve occurred in the ﬁrst postoper-
ative year, but late occlusions did occur in three stented
renal arteries (two bare stents, one covered stent) where
no signs of stenosis were apparent during follow-up. This
was probably related to distal migration of the fenestrated
component resulting in fractures in the bridging renal
stents. Despite most TV occlusion being asymptomatic,
close evaluation of TV stents during follow-up is to be rec-
ommended using appropriate CT reconstructions.
One concern regarding f-EVAR is the potential nega-
tive effect on renal function. This has been described
earlier, with a decrease in renal function in about one-
ﬁfth of patients postoperatively.2,18,19 In our series, 50%
of patients had a baseline renal dysfunction prior to treat-
ment, and the median GFR decreased signiﬁcantly over
time in 26% of the patients. Only 14% of patients with
signiﬁcant impairment had signs of decreased renal bloodﬂow during follow-up, including one patient with renal
stent occlusion that became dialysis-dependent. For the
remaining patients at least, renal impairment is probably
associated with the natural course of the aneurysmal
disease. Reports on infrarenal EVAR describe renal deteri-
oration over time, regardless of whether bare ﬁxation stents
across the renal arteries are used or not.20-22 This even
applies to open repair, where renal function is negatively
affected in the immediate postoperative period in a large
number of patients. Series that have compared open and
endovascular repair report conﬂicting results, most likely
due to selection bias. Renal status is also negatively corre-
lated to longer operation time and more proximal clamp
positioning,10,23 which is likely to negatively affect patients
undergoing open surgery for juxtarenal aneurysms.
Estimated freedom from reintervention was signiﬁ-
cantly lower than after infrarenal EVAR in the contem-
porary setting,24 with many reinterventions being
endoleak- and TV-related. Late type I endoleaks were
exclusively associated with the distal sealing zone appear-
ing at different time intervals during follow-up. This
emphasizes that, for long-term durability of the repair,
the distal sealing zone has to be of good quality as
progression of the aneurysmal disease can be expected
in the common iliac arteries.25 If both common iliacs
are dilated, we now apply unilateral iliac branch with coil-
ing of the contralateral hypogastric artery or bilateral
internal iliac branch grafts to secure a durable seal in
the external iliacs while maintaining optimal blood ﬂow
to the pelvis and left colon. Still, a majority of reinterven-
tions were due to causes other than endoleak and TV fail-
ures, with a large portion being pressure measurements
in nonshrinking and expanding aneurysms as part of an
ongoing study.26,27 In most cases, no further interven-
tion was needed, and this procedure is now almost
entirely conserved for expanding aneurysm without
apparent cause, endoleak embolization, or aspiration
and culture where graft infection is suspected. Thus,
one can expect the reintervention rate to be signiﬁcantly
reduced in the contemporary setting.
CONCLUSIONS
f-EVAR is a procedure with good short-, mid-, and
long-term results. Long-term mortality is high but mostly
nonaneurysm-related. Aneurysm-related mortality is associ-
ated with technical complications that can be reduced with
increased experience and better understanding of the stent
graft behavior. Reinterventions are common, and most
complications are detected on routine CT follow-up.
Knowledge of failure mechanisms is vital to adequately
evaluate postoperative imaging.
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